Deals

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps
HKG: 2607SHA: 601607

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607; SHA: 601607) announced that it has renewed its Sales and Distribution Agreement with Shanghai Fudan‑Zhangjiang Bio‑Pharmaceutical Co., Ltd. (HKG: 1349). Under the agreement,…

*Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal

Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
BIBiotech

Boehringer Ingelheim Partners with Sosei Group to Develop GPR52 Agonists for Schizophrenia

ADC / XDCCancer

Hansoh Pharmaceutical Secures Global Rights to Biotheus’ BsAb HS-20117/PM1080

CVDFinance

Microenergy Medical Technology Secures Pre-Series A Funding to Advance Medical Devices

Dymind BiotechnologyGetein Biotech

Getein Biotech Partners with Dymind Biotechnology to Advance IVD Market Presence

Show More